Advertisement

Search Results

Advertisement



Your search for ASCO matches 21348 pages

Showing 18351 - 18400


breast cancer

Postmenopausal Breast Cancer Risk Decreases Rapidly After Starting Regular Physical Activity

Postmenopausal women who in the past 4 years had undertaken regular physical activity equivalent to at least 4 hours of walking per week had a lower risk for invasive breast cancer compared with women who exercised less during those 4 years, according to data published recently in Cancer...

Royal Society Presents 2014 Royal Medal to Tony Hunter, PhD, FRS, Salk Professor

Tony Hunter, PhD, FRS, has been awarded the 2014 Royal Medal for Biological Sciences by the Royal Society, an international fellowship of scientists based in the United Kingdom. The award recognizes Dr. Hunter, Director of Salk Institute Cancer Center in San Diego, for his contributions to the...

breast cancer

Expect Questions and Perhaps Unrealistic Expectations

A recent study reporting the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1% for women with stage I and II breast cancer without BRCA mutations runs counter to common perceptions about the risk of contralateral breast cancer among these women and the...

breast cancer

Survival Benefit of Contralateral Prophylactic Mastectomy Less Than 1% at 20 Years, but Numbers of Procedures Have Increased

For women with stage I and II breast cancer without BRCA mutations, the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1%, regardless of age, estrogen receptor status, and cancer stage, according to a decision analysis study using a Markov model to...

Patient Guides Available Through ASCO University Bookstore

ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...

Mark Del Beccaro, MD, Named Senior Vice President, Chief Medical Officer of Seattle Children’s Hospital

Seattle Children’s has announced that Mark Del Beccaro, MD, has been appointed as Senior Vice President and Chief Medical Officer (CMO) effective October 1, 2014. Dr. Del Beccaro, who currently serves as Vice President of Medical Affairs, will replace David Fisher, MD, who is retiring. “Mark has...

Peter Pisters, MD, Appointed President and Chief Executive Officer,  University Health Network, Canada

Mr. John Mulvihill, Chair of the Board of Trustees of University Health Network (UHN), Canada, and Chair of the Board’s Selection Committee for the President and CEO, recently announced that Peter Pisters, MD, will serve as UHN’s next President and CEO, beginning January 1, 2015. Dr. Pisters is...

prostate cancer

September Is Prostate Cancer Awareness Month

In recognition of September as Prostate Cancer Awareness Month, The ASCO Post is pleased to share the following reminders, adapted in part from the American Cancer Society: Prostate cancer is the second most common cancer among men, behind skin cancer, and it affects one in seven men in his...

issues in oncology

NIH Awards Two New Grants to Explore the Understanding of Genomics Research in Africa

Two grants totaling more than $300,000 will support studies on genomic literacy among Africans as it relates to research conducted in Africa by African investigators. The 3-year grants are part of the Human Heredity and Health in Africa (H3Africa) program, funded by the National Institutes of...

gynecologic cancers
global cancer care

Gynecologic Cancer Care: Collaboration With Resource-Challenged Ethiopia

Over the past 40 years, largely because of universal Pap screening, cervical cancer deaths have been drastically reduced in the United States and other wealthy industrialized countries. However, cervical cancer is still a leading cause of cancer death among women in resource-challenged areas of the ...

How Pharmaceutical Companies Are Partnering With Patient Advocates to Ensure Access to Oncology Care

Thomas P. Sellers, MPA, has been a tireless advocate for patients’ rights for more than 20 years. A 15-year prostate cancer survivor and only child, Mr. Sellers said it was his mother’s death from lung cancer when she was 51, followed by the death of his father from glioblastoma multiforme that led ...

issues in oncology

Identifying Impending Death Helps Patients and Caregivers

Significant weight loss, cachexia, and being bedbound signal that a cancer patient is dying. However, identifying the specific signs that give physicians the ability to predict death is not well described in the literature. To better understand why predicting death is an important part of the care...

ASTRO Awards $35,500 in Individual Grants to 43 Researchers

The American Society for Radiation Oncology (ASTRO) has selected 43 recipients to receive a total of $35,500 for the 2014 Annual Meeting Abstract Awards. The awardees will be recognized at ASTRO’s 56th Annual Meeting. ASTRO’s 56th Annual Meeting, takes place San Francisco’s Moscone Center,...

leukemia

Program Offers Unique Intervention for Acute Promyelocytic Leukemia

If Anand P. Jillella, MD, has his way, no future patient with acute promyelocytic leukemia (APL) will experience a delay in treatment or lack for an expert consult—and few, if any, will die of this condition. Mortality from APL is much higher than most oncologists think, especially during the first ...

lung cancer

Failure of IGF-1R Inhibitor Figitumumab in Advanced Nonadenocarcinoma Non–Small Cell Lung Cancer

The vast majority of non–small cell lung cancer (NSCLC) patients present with advanced disease, and many will develop metastases after primary curative therapy. Until recently, despite its low efficacy, chemotherapy remained the only treatment modality in metastatic NSCLC. Within the past decade,...

Leaders in Health Disparities Honored

The W. Montague Cobb/National Medical Association (NMA) Health Institute (Cobb Institute) was established by the National Medical Association to develop, evaluate, and implement strategies to promote wellness and eliminate health disparities and racism in medicine. The Institute recently celebrated ...

AACI Members Elect New Leadership, Members to Board of Directors

The Association of American Cancer Institutes (AACI) has announced the election of Stanton L. Gerson, MD, as Vice-President/President-Elect for a 6-year term, effective in October 2014. Dr. Gerson is the Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology,...

ASCO Launches the ASCO in Action Beat

ASCO has launched the ASCO in Action Beat, an e-newsletter specifically focused on the latest news and updates related to cancer policy from ASCO in Action. The ASCO in Action Beat provides a snapshot of the most significant news and updates in cancer policy, ASCO’s ongoing advocacy efforts, and...

Registration Open for the Community Research Forum Annual Meeting

Registration is open for the ASCO Community Research Forum Annual Meeting, September 28 to 29, 2014, at ASCO headquarters in Alexandria, Virginia. Join fellow community-based researchers to discuss barriers and develop solutions to common challenges faced in the community research setting. This...

ASCO Offers Input on 21st Century Cures PCAST White Paper

ASCO submitted a letter to the U.S. House Energy and Commerce Committee responding to the committee’s second white paper on its 21st Century Cures Initiative, 21st Century Cures: An Update on the President’s Council of Advisors on Science and Technology (PCAST) 2012 Report on Propelling ...

A World Free From the Fear of Cancer—Is It Possible?

By every definition, ASCO’s 50th Annual Meeting was a huge success. The halls were buzzing as nearly 35,000 attendees shared excitement about cancer research.   This was a banner year for federally funded clinical trials—all four of the abstracts selected for ASCO’s Plenary Session were backed by...

ASCO Experts Discuss the Latest Advances in Breast Cancer Care

The 2014 Breast Cancer Symposium will take place September 4 to 6. Direct your patients to www.cancer.net/blog to listen to ASCO Experts explain some of the research announced prior to the meeting and discuss what this research means for patient care. They can also read a summary of the research...

#WeConquerCancer: Creative Fundraisers From Committed Conquerors

Conquer Cancer Foundation donors are a consistently creative bunch when it comes to encouraging others to help conquer cancer: Tyler invited his friends and family to a charity spin class; elementary school students in Malibu, California, sold bracelets in honor of their principal; Steve competed...

A Conversation With Lidia Schapira, MD, the New JCO Art of Oncology Editor

The popular Art of Oncology (AOO) section of the Journal of Clinical Oncology (JCO) brings a human perspective to the art and science of practicing oncology. Lidia Schapira, MD, FASCO, Assistant Professor at Harvard Medical School and Massachusetts General Hospital, became the Art of Oncology...

breast cancer

Palbociclib Expanded Access Program Open to Eligible Breast Cancer Patients

Pfizer Inc announced that the company has initiated a multicenter, open-label expanded access program in the United States for the investigational oral CDK 4/6 inhibitor, palbociclib. Through the program, palbociclib is being made available for use in combination with ­letrozole for postmenopausal...

palliative care

The Role of Integrated Palliative Care in Radiation Oncology

Three years ago, Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, launched a Supportive and Palliative Radiation Oncology (SPRO) program to integrate generalist palliative oncology services, including the physical, psychosocial, and spiritual aspects of care, into radiation...

Expert Point of View: Wyndham H. Wilson, MD, PhD

Since the presentation on mediastinal lymphoma at the Pan Pacific Lymphoma Conference, Wyndham H. Wilson, MD, PhD, Chief of the Hematological Malignancies Therapeutics Section, Metabolism Branch, Cancer Research Center, of the National Cancer Institute in Bethesda, Maryland, offered The ASCO Post...

multiple myeloma

FDA Approves Bortezomib Retreatment in Patients With Multiple Myeloma

The U.S. Food and Drug Administration has approved bortezomib (Velcade) for the retreatment of adult patients with multiple myeloma who had previously responded to bortezomib therapy and relapsed at least 6 months following completion of prior bortezomib treatment. The labeling update includes...

gynecologic cancers

FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer

The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication is approved for use in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The FDA ...

hematologic malignancies

FDA Grants Fast Track Designation to Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

The U.S. Food and Drug Administration has granted Fast Track designation to pacritinib for the treatment of intermediate- and high-risk myelofibrosis, including patients with disease-related thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are suboptimally...

colorectal cancer

FDA Approves First Noninvasive DNA Screening Test for Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or...

prostate cancer

Systematic Model Identifies Factors Associated With Adherence in Prostate Cancer Prevention Trial

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo an end-of-study biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The Prostate Cancer Prevention Trial...

colorectal cancer

Understanding the Impact of Results From CALGB/ SWOG 80405 and Other New Data in Colorectal Cancer

The Cancer and Leukemia Group B (CALGB)/Southwest Oncology Group (SWOG) 80405 trial, presented during the Plenary Session at this year’s ASCO Annual Meeting, demonstrated that cetuximab (Erbitux) and bevacizumab (Avastin) confer similar benefits as first-line treatment with chemotherapy for KRAS...

Charles LeMaistre, MD, and Hans Mark, PhD, Named Chancellors Emeritus by the University of Texas System Board of Regents

Two former Chancellors, Charles ­LeMaistre, MD, and Hans Mark, PhD, were recently given the honorific title Chancellors Emeritus by the University of Texas System Board of Regents.  “Charles LeMaistre and Hans Mark were visionary chancellors who expanded the UT System into new directions that...

leukemia

Emerging Approaches in Acute Myeloid Leukemia

With the emergence of molecular diagnostics and new therapeutics, the treatment of acute myeloid leukemia (AML) is entering a new era. Hugo F. Fernandez, MD, Associate Chief of Blood and Marrow Transplantation at Moffitt Cancer Center in Tampa, Florida, spoke with The ASCO Post about how he...

multiple myeloma

Treating Multiple Myeloma in 2014

The field of multiple myeloma is rapidly changing, and the shifts that are occurring impact the management of these patients, from initial diagnosis through multiple relapses. At the 9th Annual New Orleans Summer Cancer Meeting, Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant...

gynecologic cancers

September Is Ovarian Cancer Awareness Month

In recognition of September as Ovarian Cancer Awareness month, David A. Fishman, MD, Director of the Mount Sinai Ovarian Cancer Risk Assessment Program and Professor and Fellowship Director in the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine at...

lung cancer

Targeting KRAS Mutations in Lung Cancer: No Longer Impossible

The KRAS mutation has long been considered “undruggable,” but new approaches in drug development may change this. The end result could be effective new treatment options for KRAS-mutated non–small cell lung cancer (NSCLC), according to David R. Gandara, MD, who described the emerging findings at...

lymphoma

Study Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma

Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the...

Expert Point of View: Richard L. Schilsky, MD

Information on the drivers of cancer care is important in helping to deliver higher-quality and potentially less costly cancer treatments, noted Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, in a commentary accompanying the study by ­Dotan et al.1 Moreover, practice change can be a complex ...

issues in oncology

Oncology Practice: What Are the Factors Driving Change?

Clinical practice changes in response to new medical evidence, but not always immediately or all at once. So what else determines whether and how quickly practice changes in response to evidence, for instance, that a widely used drug is effective only in patients with a certain biomarker? In a new...

issues in oncology

My Priorities for the Year Ahead

I am honored and privileged to lead ASCO during its 51st year, a year that promises to bring both challenges and opportunities to our members and our patients. As the theme for my Presidential term, I’ve chosen Illumination and Innovation: Transforming Data Into Learning, because we are positioned...

lung cancer

Stereotactic Body Radiation Therapy an Effective Option for Early-Stage Lung Cancer Patients

Stereotactic body radiation therapy (SBRT) is safe and effective in early-stage non–small cell lung cancer (NSCLC), as it confers local control in 90% or more patients with T1 disease, according to Roy Decker, MD, PhD, Associate Professor in the Department of Therapeutic Radiology at Yale Cancer...

St. Jude Children’s Research Hospital Mourns Loss of Friend, Supporter, Robin Williams

St. Jude Children’s Research Hospital acknowledged the death of Robin Williams with the following statement: “On August 11, 2014, the world lost an iconic man and entertainer, and St. Jude Children’s Research Hospital lost an incredible friend and supporter. Robin Williams generously gave his time...

John H. Saiki, MD, SWOG Investigator, Dies at 77

John “Jack” Harris Saiki, MD, Professor Emeritus at the University of New Mexico Department of Medicine, Hematology/Oncology Division, lived the history of modern day oncology with a career spanning 44 years. In the early days of his career, with the support of a grant from the federally funded New ...

solid tumors

How Evolutionary Game Theory Is Offering Clues to Disrupt Cancer Cell Metabolism

Kenneth J. Pienta, MD, and his colleagues at Johns Hopkins Medicine in Baltimore are using the principles of evolutionary game theory to learn how cancer cells cooperate within a tumor to gather energy and metastasize. Game theory, the mathematic study of strategic decision-making that is commonly...

Residents Association Recognizes 57 Mentors and Teachers With 2014 Educator of the Year Award

The Association of Residents in Radiation Oncology (ARRO) has honored 57 educators with the 2014 Educator of the Year Award. The award, presented annually, recognizes outstanding teachers and mentors of radiation oncology residents. Each radiation oncology residency program may nominate one faculty ...

‘Everybody Has a Mutation or More’

While genome sequencing is not currently recommended or widely used because of its high cost and paucity of meaningful, actionable results, some patients wouldn’t want it even if it were free and useful, ­Theodora Ross, MD, PhD, Director of the Cancer Genetics Program at the University of Texas...

breast cancer

News of Mutations in PALB2 Gene Raising Risk of Breast Cancer Offers Opportunity to Explain Limits of Genetic Testing

The response among patients to news reports about mutations in a gene known as PALB2 raising the risk of breast cancer “has been predictable,” Theodora Ross, MD, PhD, wrote in The New York Times.1 As an example, Dr. Ross, Director of the Cancer Genetics Program at The University of Texas...

Patient Guides Available Through ASCO University Bookstore

ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...

Advertisement

Advertisement




Advertisement